Predictors of malignancies and overall mortality in <scp>J</scp>apanese patients with biopsy‐proven non‐alcoholic fatty liver disease

Seko, Yuya; Sumida, Yoshio; Tanaka, Saiyu; Taketani, Hiroyoshi; Kanemasa, Kazuyuki; Ishiba, Hiroshi; Okajima, Akira; Nishimura, Takeshi; Yamaguchi, Kanji; Moriguchi, Michihisa; Mitsuyoshi, Hironori; Yasui, Kohichiroh; Minami, Masahito; Itoh, Yoshito

doi:10.1111/hepr.12407

Cited by 33 publications

(52 citation statements)

References 41 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the idea that fibrosis is a main factor that defines the prognosis of NASH is common. It is reported that the risk of developing liver‐related events significantly increases with the progress of hepatic fibrosis, and liver fibrosis is a risk factor for liver carcinogenesis . Therefore, there is no doubt that hepatic fibrosis is an important prognostic factor for NASH.…”

Section: Discussionmentioning

confidence: 99%

Serum C16:1n7/C16:0 ratio as a diagnostic marker for non‐alcoholic steatohepatitis

Yamada

Mizukoshi

Seike

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aims Accurate diagnosis of non‐alcoholic steatohepatitis (NASH) from non‐alcoholic fatty liver disease (NAFLD) is clinically important. Therefore, there is a need for easier ways of diagnosing NASH. In this study, we investigated the serum fatty acid composition and evaluated the possibility of using the serum fatty acid composition as a diagnostic marker of NASH. Methods The subjects were 78 NAFLD patients (non‐alcoholic fatty liver [NAFL]: 30, NASH: 48) and 24 healthy individuals. Fatty acids extracted from the liver tissue and serum were identified and quantified by gas chromatography. In addition, we evaluated the relationship between serum and liver tissue fatty acid composition, patient background, and liver histology. The diagnostic performance of NASH was evaluated by calculating the area under the receiver operating characteristic (AUROC). Results The results of the fatty acid analysis showed the C16:1n7/C16:0 ratio to have the strongest correlation between serum and liver tissue (r = 0.865, P < 0.0001). The serum C16:1n7/C16:0 ratio in the NASH group was higher compared with that in the NAFL group (P = 0.0007). Evaluation of the association of the serum C16:1n7/C16:0 ratio with liver histology revealed significant correlation with lobular inflammation score, ballooning score, and fibrosis score. The AUROC for predicting NASH in all NAFLD patients was 0.7097. The AUROC was nearly equivalent even when the study subjects were restricted to patients with a fibrosis score ≤ 2 only (AUROC 0.6917). Conclusion Measuring the serum C16:1n7/C16:0 ratio may be an effective non‐invasive method for diagnosing NASH, particularly in its early stages.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum C16:1n7/C16:0 ratio as a diagnostic marker for non‐alcoholic steatohepatitis

Yamada

Mizukoshi

Seike

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Metabolic syndrome, including type 2 diabetes mellitus and obesity, has been reported to be an independent risk factor for HCC . We previously clarified that severe fibrosis was an independent risk factor in hospital‐based Japanese patients with biopsy‐proven NAFLD …”

Section: Introductionmentioning

confidence: 99%

Development of hepatocellular carcinoma in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression

Seko

Sumida

Tanaka

et al. 2016

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Approximately 10% of NAFLD cases are considered non-alcoholic steatohepatitis (NASH), which can progress to potentially fatal cirrhosis and liver cancer [4][5][6][7]. The increased prevalence of NAFLD is a serious health problem in many countries including Japan [8,9]. NASH has recently attracted attention as a cause of progressive chronic liver disease of non-viral etiology; thus, distinguishing severe fibrosis from non-severe fibrosis in NASH is indispensable [10].…”

Section: Introductionmentioning

confidence: 99%

Serum Immunoreactive Collagen IV detected by Monoclonal Antibodies as a Marker of Severe Fibrosis in Patients with Non- Alcoholic Fatty Liver Disease

Aida

Abe

Tomita

et al. 2015

JGLD

View full text Add to dashboard Cite

Background & Aims: The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. We evaluated serum collagen IV as a direct non-invasive marker of severe liver fibrosis in NAFLD.Methods: The study included 148 NAFLD and 187 chronic hepatitis C patients in whom histological severity of liver fibrosis was evaluated. The utility of serum collagen IV measured by immune-mediated agglutination using two types of monoclonal antibodies for distinguishing severe fibrosis (≥ stage 3 and ≥ F3) from non-to-moderate fibrosis in NAFLD or chronic hepatitis C was assessed in comparison to serum hyaluronic acid or other indirect fibrosis markers.Results: Multiple logistic regression analysis showed that serum collagen IV was significantly associated with severe fibrosis in NAFLD (odds ratio: 1.21, p<0.001) but not in chronic hepatitis C. For distinguishing severe fibrosis in NAFLD, collagen IV showed the largest area under the receiver-operating characteristic curve (0.827, 95%CI: 0.746-0.908) followed by FIB-4 (0.805, 95%CI: 0.728-0.890); in chronic hepatitis C, those for FIB-4 (0.813, 95%CI: 0.748-0.878) and collagen IV (0.770, 95%CI: 0.683-0.857) were the largest and smallest, respectively. To detect severe fibrosis in NAFLD, a cutoff of collagen IV > 177 exhibited 77.1% sensitivity, 84.0% specificity, 76.5% positive predictive value, and 84.0% negative predictive value. Combined with a cutoff of FIB-4 > 2.09, the negative and positive predictive values, and specificity for detecting severe fibrosis in NAFLD increased further.Conclusion: Collagen IV is a reliable marker for distinguishing severe liver fibrosis from non-to-moderate fibrosis in NAFLD but not chronic hepatitis C.

show abstract

Predictors of malignancies and overall mortality in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease

Abstract: The incidence of extrahepatic cancer was higher than that of HCC. Severe fibrosis was a predictor for HCC. Patients with NAFLD and elevated type IV collagen 7s levels are at increased risk for extrahepatic cancer and overall mortality.

Cited by 33 publications

References 41 publications

Serum C16:1n7/C16:0 ratio as a diagnostic marker for non‐alcoholic steatohepatitis

Serum C16:1n7/C16:0 ratio as a diagnostic marker for non‐alcoholic steatohepatitis

Development of hepatocellular carcinoma in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression

Serum Immunoreactive Collagen IV detected by Monoclonal Antibodies as a Marker of Severe Fibrosis in Patients with Non- Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About